Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Methods. 2013 Oct 1;65(1):139–147. doi: 10.1016/j.ymeth.2013.09.015

Figure 2.

Figure 2

Overview of salient features of intact antibodies, enzymatic fragments such as F(ab′)2 and Fab, and engineered fragments including minibody, diabody/cys-diabody (cys-db), and scFv.